20,092
Participants
Start Date
October 18, 2017
Primary Completion Date
November 1, 2019
Study Completion Date
November 1, 2019
2 drug dose - DA
Lymphatic Filariasis Mass Drug Administration (MDA) with the currently used standard of care combination drug therapy of diethylcarbamazine and albendazole (DA)
3 drug dose - IDA
Lymphatic Filariasis Mass Drug Administration (MDA) with triple drug therapy of ivermectin, diethylcarbamazine, and albendazole (IDA)
Vector Control Research Centre, Puducherry
Ministry of Health and Medical Services, Suva
Ministere de la Sante Publique et de la Population, Port-au-Prince
Universitas Indonesia, Jakarta
Papua New Guinea Institute for Medical Research, Madang
Case Western Reserve University
OTHER
Ministere de la Sante Publique et de la Population, Haiti
UNKNOWN
Indonesia University
OTHER
Papua New Guinea Institute for Medical Research
UNKNOWN
Washington University School of Medicine
OTHER